EUVIMEDEUVIMED entdecken
Crossref

Medical treatment and comorbidity in polycystic ovary syndrome: An updated review

Dorte Glintborg, Marianne Andersen

Current Opinion in Endocrine and Metabolic Research · 2020-06 · 12 · 33-40

DOI: 10.1016/j.coemr.2020.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Opinion in Endocrine and Metabolic Research, 2020-06. Verfasst von Dorte Glintborg und 1 weiteren Autor:innen. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is defined by hyperandrogenism, irregular menses, and polycystic ovaries when other etiologies are excluded. The risk of type 2 diabetes and cardiovascular disease is increased in PCOS. Furthermore, the immune function in PCOS is impaired with elevated circulating of autoantibodies and increased risk of thyroid disease. Especially obese women with PCOS are at increased risk of nonalcoholic fatty liver disease. Medical treatment of PCOS involves antiandrogen treatment in combination with insulin sensitizing drugs. Oral contraceptives are often applied as antiandrogens, but spironolactone could have additional vascular benefits. New and upcoming treatments for PCOS involve GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors, myoinositol, thyroid hormones, and vitamin supplements. Statins are rarely indicated for treatment of dyslipidemia in PCOS, but statins could improve PCOS phenotype. Use of antidepressants in PCOS could have adverse effects on PCOS metabolic phenotype. In the present article, we give an update regarding established and upcoming medical treatment for PCOS and for comorbidities of PCOS.

Zitieren

APA

Glintborg, D., & Andersen, M. (2020). Medical treatment and comorbidity in polycystic ovary syndrome: An updated review. Current Opinion in Endocrine and Metabolic Research, 12, 33-40. https://doi.org/10.1016/j.coemr.2020.02.014

Vancouver

Glintborg D, Andersen M. Medical treatment and comorbidity in polycystic ovary syndrome: An updated review. Current Opinion in Endocrine and Metabolic Research. 2020;12:33-40. doi:10.1016/j.coemr.2020.02.014

BibTeX
@article{Glintborg2020,
  author = {Glintborg, Dorte and Andersen, Marianne},
  title = {Medical treatment and comorbidity in polycystic ovary syndrome: An updated review},
  journal = {Current Opinion in Endocrine and Metabolic Research},
  year = {2020},
  volume = {12},
  pages = {33--40},
  doi = {10.1016/j.coemr.2020.02.014}
}
Kostenlos starten →